

## **Courtagen Life Sciences Appoints Reymundo Lozano, MD to the Company's Clinical And Strategic Advisory Board.**

*Dr. Lozano Brings Deep Clinical Expertise And Knowledge In Pediatric Genetics to Courtagen's SAB*

WOBURN, MA. April 3-, 2015 - Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the appointment of Reymundo Lozano, MD to the company's Clinical and Strategic Advisory Board.

"Dr. Lozano has deep domain knowledge in pediatric genetics, specifically in the areas of intellectual disabilities and the autism spectrum disorders," states Brian McKernan, Chief Executive Officer of Courtagen. "We look forward to benefiting from Dr. Lozano's insights as we continue to build a world class molecular information company."

Dr. Lozano is a Pediatric Geneticist, who has dedicated his research to better understanding the molecular basis of genetic disorders associated with intellectual disabilities and autism spectrum disorders (ASD). He is an International Medical Graduate from Mexico and completed his subspecialty studies at UCLA. He specializes in the treatment of neurodevelopmental genetic syndromes including fragile X syndrome (FXS), Angelman syndrome, 15q duplication syndrome, 22q11 microdeletion syndrome, and Noonan syndrome and other RASopathies. His work focuses on different clinical trials for ASD and FXS. Dr. Lozano is dedicated to finding better treatments, and eventually the cure for neurodevelopmental disorders. He is also studying the phenotypic variability of fragile X premutation carriers and the additive effects of other "genetic hits" and environmental exposures. He pursues the genetic diagnosis of ASD, using cutting edge technology, including microarrays, mitochondrial function, and whole exome sequencing.

### **About Courtagen Life Sciences, Inc.**

Courtagen is a privately held life sciences and molecular information company that converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, Courtagen focuses on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders. Courtagen's state-of-the-art Next-Generation Sequencing clinical laboratory integrates genotype, phenotype, and disease mechanism data using cloud-based computing and custom analytical methods to provide the most comprehensive results for clinicians, patients, and their families to better understand and treat their disease. More information can be found at [www.courtagen.com](http://www.courtagen.com).

Contact:

Mike Catalano  
[mike.catalano@courtagen.com](mailto:mike.catalano@courtagen.com)  
877-395-7608